Gadobenate dimeglumine——一个新的造影剂成像先生:初步评估在健康的志愿者。

文章的细节

引用

复制到剪贴板

Vogl TJ, Pegios W,麦克马洪C,鲍尔泽J, Waitzinger J, Pirovano G,莱斯那J

Gadobenate dimeglumine——一个新的造影剂成像先生:初步评估在健康的志愿者。

杂志是J Roentgenol。1992年4月,158 (4):887 - 92。

PubMed ID

1546612 (在PubMed

]

文摘

Gadobenate dimeglumine(原名Gd-BOPTA)是最近开发了顺磁性造影剂,经历胆汁以及肾排泄。因此,它可能是有用的在肝脏成像先生。其安全性、宽容和实用性在8名健康受试者可视化肝胆管的结构进行了研究。轴向腹部与t1加权图像得到旋转回声和gradient-echo序列在1.5 T之前和之后的第四管理gadobenate dimeglumine剂量的0.005,0.05,0.1,和0.2更易/公斤体重。两个受试者接受剂量。政府每公斤0.1更易导致gradient-echo序列的最大肝脏增强149%和90%的t1加权旋转回声序列后60分钟注入。的对比度增强肝脏保持2小时几乎不变。信噪比的胆道从38岁增加到121 2小时后gradient-echo图像。除此之外,还有重要的对比度增强肾脏。最优实现可视化的肝实质与剂量的0.05和0.1更易gadobenate dimeglumine /公斤。 Mild to moderate side effects such as nausea and retching, a sense of warmth at the infusion site, and transient pruritus lasting 1 min were reported by three (38%) of the subjects. The initial results of the first application of gadobenate dimeglumine in humans are encouraging because the contrast agent appears to be reasonably well tolerated at the doses appropriate for hepatobiliary imaging. Further clinical studies of this contrast agent are warranted to assess its effect on liver lesion conspicuity and the frequency with which side effects occur.

DrugBank数据引用了这篇文章

药物

Gadobenic酸